Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Overview
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Companies Involved in Therapeutics Development
Avex Life Sciences Corp
Apnimed Inc
Dermavant Sciences Inc
Karu Therapeutics Inc
Sinsin Pharmaceutical Co Ltd
TheraVida Inc
Trigone Pharma Ltd
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Drug Profiles
(atomoxetine + oxybutynin) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(lidocaine + oxybutynin) SR - Drug Profile
Product Description
Mechanism Of Action
History of Events
(oxybutynin + pilocarpine) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(oxybutynin + reboxetine) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(pilocarpine + tolterodine) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(trospium chloride + xanomeline) - Drug Profile
Product Description
Mechanism Of Action
History of Events
AD-109 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AVEX-141 - Drug Profile
Product Description
Mechanism Of Action
History of Events
blarcamesine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
oxybutynin - Drug Profile
Product Description
Mechanism Of Action
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Dormant Products
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Discontinued Products
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Product Development Milestones
Featured News & Press Releases
May 18, 2022: Karu Therapeutics to host virtual event highlighting clinical program for psychosis in Alzheimer’s disease
Mar 15, 2022: Avex Life Sciences announces presentation of phase 2 clinical biomarker data from Avex 2-73-PDD-001 Parkinson’s disease dementia study at AD/PD? 2022 Intertiol Conference
Mar 09, 2022: Apnimed study APC-004 phase 2 data to be presented at World Sleep 2022
Feb 04, 2022: Avex life sciences provides supplemental information on AVEX 2-73 (blarcamesine) AVATAR Phase 3 trial for the treatment of adult patients with Rett syndrome
Feb 01, 2022: AVEX 2-73 (Blarcamesine) AVATAR phase 3 trial met primary and secondary efficacy endpoints
Dec 16, 2021: Apnimed announces dosing of first patient in phase 3 MARIPOSA confirmatory trial of AD504, a potential nighttime oral treatment for Obstructive Sleep Apnea (OSA)
Oct 13, 2021: Avex Life Sciences reports data review by the independent DSMB reported for phase 2b/3 trial of AVEX 2-73 for AD
Oct 13, 2021: Apnimed announces positive phase 2 (Study APC-003) data demonstrating durability-of-effect and improved quality-of-life in patients with obstructive sleep apnea after investigatiol AD109 treatment
Oct 13, 2021: Apnimed announces positive phase 2 data (Study APC-004) demonstrating improvement in measures of obstructive sleep apnea and a dose-response with AD109, an oral pharmacologic investigatiol treatment for the disease
Sep 13, 2021: Novamind to serve as research site for Karu Therapeutics late-stage clinical trial
Aug 26, 2021: Avex Life Sciences announces publication of Foundatiol data for AVEX2-73 (blarcamesine) in Fragile X syndrome (Autism)
Aug 13, 2021: Trigone Pharma announces the initiation of a phase 2 clinical trial of TRG-100 in patients with interstitial cystitis/bladder pain syndrome
Jul 29, 2021: Avex Life Sciences announces AVEX2-73 (Blarcamesine) significantly prevented A? (Abeta)-induced cognitive deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s Disease
Jul 22, 2021: Trigone Pharma to present preclinical data for TRG-100 in interstitial cystitis / bladder pain syndrome at the upcoming American Urological Association Conference (AUA) in September 2021
Jun 29, 2021: Avex reports positive data from Parkinson’s disease dementia study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Type, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Anavex Life Sciences Corp, 2022
Pipeline by Apnimed Inc, 2022
Pipeline by Dermavant Sciences Inc, 2022
Pipeline by Karuna Therapeutics Inc, 2022
Pipeline by Sinsin Pharmaceutical Co Ltd, 2022
Pipeline by TheraVida Inc, 2022
Pipeline by Trigone Pharma Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022